Mindset Pharma Inc. (“Mindset” or the “Company”) is pleased to announce that it has completed an equity financing for total proceeds of $704,835. Mr. Richard Patricio, founder and Director of Mindset Pharma commented, “Interest in the psychedelic space has exploded since we formed Mindset in mid- 2019. Our business plan remains to create an IP portfolio of novel psychedelic compounds for treatment of neurological and psychiatric disorders. With this financing in place and the recent filing of provisional patent applications we are now positioned to rapidly execute the next several steps in this plan namely synthesizing several compounds for metabolite profiling and receptor screening. These are the first steps in creating less toxic, more efficacious drug candidates. We look forward to updating our new shareholders on progress in due course.”
About Mindset Pharma
Mindset Pharma is a drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Founded by serial entrepreneurs and domain experts in drug development and medicinal chemistry and based in Toronto, Canada, Mindset is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychiatric disorders efficiently and safely.
